http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013059442-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e2285edbbe70ae81838245ae616e11d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3507074ab5d169ae97a1529a1736c369
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1763896613178524211bd0e92d69e6f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y102-01036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
filingDate 2012-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf56e029ae07392a9a8e08374249b1cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7840c5e357aba822289890a0f2e6a833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f503f53bad91681b62bc2d524d54d72
publicationDate 2015-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2013059442-A3
titleOfInvention Inhibition of retinoic acid production for hiv vaccination
abstract A method and vaccine composition compressing a siRNA and/or a shRNA that targets a retinoic acid producing enzyme and an antigen. Silencing retinoic acid producing enzymes downregulates α4β7 expression on activated T and B cells. Immunization with a retinoic acid silencing mechanism greatly enhanced anti-HIV gp140 immune responses in the vaginal tract and periphery but not in the intestine, providing a unique strategy to redistribute anti-HIV mucosal immune responses on the front line of defense against HIV-1 with concomitant suppression of α4β7high CD4+ T cells.
priorityDate 2011-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008279812-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010127166-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395397

Total number of triples: 35.